GVK Biosciences (GVK BIO), Asia's leading discovery research and development organisation, today unveiled a new brand 'Clinogent' in the clinical development area.
Clinogent provides end-to-end clinical development services, from offering bioequivalence studies for generic pharma and late phase patient based clinical studies for research based companies, GVK BIO CEO Manni Kantipudi told reporters here.
"Clinogent will be a unique clinical development service provider from India, as it will be able to address the clinical needs of both innovator bio-pharmaceutical and generics companies world-wide. I am confident this step will bring greater focus on delivering innovative and intelligent solutions," Kantipudi said.
The clinical development industry pegged at USD 16 billion is set to grow at a steady 10.5 per cent to USD 23 billion by 2020.
He said that the recent mergers and acquisitions within pharma and generics space only indicate that companies are focusing on their core competence and outsource large segments of their R&D process.
Clinogent is uniquely positioned as a comprehensive full service clinical development solutions organisation that will cater to end-to-end research and development solutions to the pharmaceutical, generics, biotechnology companies, and academic institutions across the globe with the focus markets being USA, Europe and Asia, Kantipudi added.
The launch of a new brand is a part of GVK BIO's growth plan in taking the organisation to the next level and creating a benchmark in the industry, he said.
